Inhibition of MT-450 rat mammary tumour growth by antibodies recognising subtypes of blood group antigen B

Oncogene. 1999 Aug 5;18(31):4485-94. doi: 10.1038/sj.onc.1202808.

Abstract

Using subtractive immunization to identify cell surface epitopes expressed in a metastasis-specific fashion on cells of the rat MT-W9 mammary carcinoma model, we generated a monoclonal antibody called M-N#1. This antibody binds specifically to metastasizing cells of the MT-W9 series and also to certain other metastasizing rat mammary carcinoma cell lines. We demonstrate that the M-N#1 antibody recognizes a fucosylated N-glycosyl sugar modification, and furthermore show that the epitope specificity of the M-N#1 antibody is for blood group antigen B subtypes 2, 3 and 4 with slight cross-reactivity with blood group antigen A subtype 2. The expression of these carbohydrate epitopes on MT-450 cells is functionally important, because the M-N#1 antibody efficiently inhibits MT-450 tumour growth in spontaneous metastasis assays. These results suggest that expression of the subtypes of blood group antigen B recognized by the M-N#1 antibody does not directly participate in the metastatic cascade but rather confers a growth or survival advantage on the tumour cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ABO Blood-Group System / immunology*
  • Animals
  • Antibodies, Monoclonal / pharmacology*
  • Cell Division*
  • Cell Line
  • Female
  • Humans
  • Mammary Neoplasms, Experimental / immunology
  • Mammary Neoplasms, Experimental / pathology*
  • Neoplasm Metastasis
  • Rats
  • Rats, Inbred WF
  • Tumor Cells, Cultured

Substances

  • ABO Blood-Group System
  • Antibodies, Monoclonal